Ozempic side effects: what the data actually shows
Published by GLP-1 Picks · AI-assisted editorial research · Updated October 23, 2026
Important: Ozempic is FDA-approved for type 2 diabetes
Ozempic injection is approved to improve blood-sugar control in adults with type 2 diabetes. Its indication to reduce the risk of major cardiovascular events is for adults with T2DM and established cardiovascular disease. It is not FDA-approved for weight loss.
The same active molecule (semaglutide) is also marketed under the brand name Wegovy, which IS FDA-approved for chronic weight management.
The common-side-effect table below reports 0.5 mg and 1 mg groups from placebo-controlled trials in adults with type 2 diabetes. It does not give rates for every dose or population.
For the weight-management product, see the Wegovy side effects deep dive if you're prescribed semaglutide for weight loss.
The most common Ozempic side effects at diabetes doses are gastrointestinal: nausea (15.8% at 0.5mg / 20.3% at 1mg), diarrhea (8.5-8.8%), vomiting (5-9.2%), and abdominal pain (5.7-7.3%) in the cited trials.
These percentages do not predict your symptoms or when they will occur.
All percentages below come from the FDA-approved Ozempic prescribing information, based on the SUSTAIN program of clinical trials.
Warning signs: when to seek medical help
- • Severe abdominal pain that does not go away, with or without vomiting: stop Ozempic and contact your healthcare professional right away; pain may reach your back.
- • Symptoms of low blood sugar: follow the plan your clinician gave you, especially if you also use insulin or a sulfonylurea.
- • Symptoms of a serious allergic reaction, such as breathing difficulty or throat swelling: stop Ozempic and get medical help right away.
- • Changes in vision: contact your clinician, including if you have a history of diabetic retinopathy.
- • Persistent nausea, vomiting, or diarrhea: contact your clinician promptly about possible dehydration; do not wait for a fixed number of hours.
- • Upper abdominal pain, fever, jaundice, or clay-colored stools: contact your clinician about possible gallbladder problems.
If you are experiencing a medical emergency, call 911.
Report any serious adverse event to FDA MedWatch.
Common side effects: rates from the Ozempic label
Source: section 6.1, Table 1 and the accompanying gastrointestinal reactions paragraph in the FDA-approved Ozempic prescribing information.
These are 0.5 mg and 1 mg groups from placebo-controlled trials in adults with type 2 diabetes, not a prediction of symptom severity or duration.
| Side effect | Rate at 0.5mg | Rate at 1mg |
|---|---|---|
| Nausea | 15.8% | 20.3% |
| Diarrhea | 8.5% | 8.8% |
| Vomiting | 5.0% | 9.2% |
| Abdominal pain | 7.3% | 5.7% |
| Constipation | 5.0% | 3.1% |
| Dyspepsia (indigestion) | 3.5% | 2.7% |
The label reports injection-site reactions in 0.2% of Ozempic-treated patients across the placebo-controlled trials, not as separate rates for each dose.
Low-blood-sugar rates vary by the other medicine used and the definition of the event; ask your clinician for an individual low-blood-sugar plan.
How do dose changes affect symptoms?
Reported nausea, vomiting and diarrhea can occur during dose increases. Trial percentages do not tell you which week a symptom will start or stop.
Follow your prescriber's instructions for your exact product and indication, and contact them about troublesome symptoms before changing your dose.
The Ozempic prescribing information, section 2 explains the dosing instructions. It is a reference for your clinician, not a schedule to advance through automatically.
What should you ask your prescriber about side effects?
- Describe the symptom, when it started, your current dose and your most recent dose change.
- Explain whether eating, drinking or daily activities are affected. Persistent or severe symptoms need clinical assessment.
- For routine symptoms, ask your clinician before changing Ozempic, insulin or sulfonylureas. Follow the urgent instructions above if those warning signs occur.
- Ask which symptoms require urgent help and how to contact the care team between appointments.
Use the Ozempic prescribing information and Medication Guide alongside this checklist. For help recording symptoms and preparing questions, see our symptom-management guide.
FDA's January 2026 review found no increased risk of suicidal thoughts or behavior with GLP-1 medicines.
Mood changes still deserve care: tell your clinician about new or worsening depression or suicidal thoughts. Call or text 988 for crisis support; call 911 for immediate danger.
Serious side effects, recognize these red flags
This is not a complete list of warnings or possible side effects. Use the full prescribing information and Medication Guide with your clinician. The Ozempic label calls for monitoring people with a history of diabetic retinopathy; ask your clinician what monitoring you need.
Pancreatitis
Reported in clinical trials; requires urgent assessmentRed-flag symptoms: Severe or persistent abdominal pain that may reach your back, with or without nausea or vomiting
Action: Stop Ozempic and contact your healthcare professional right away if pancreatitis is suspected.
Diabetic retinopathy complications
3.0% vs 1.8% on placebo in a 2-year trial in adults with type 2 diabetes and high cardiovascular riskRed-flag symptoms: New or worsening blurred vision, especially in patients with pre-existing diabetic retinopathy. Rapid improvement in blood glucose can transiently worsen retinopathy in vulnerable patients.
Action: Tell your clinician about any history of diabetic retinopathy and any vision changes. Ask what eye monitoring is appropriate for you.
Gallbladder problems
Gallstones: 1.5% at 0.5 mg and 0.4% at 1 mg; none reported on placebo in these trialsRed-flag symptoms: Upper abdominal pain, fever, jaundice, or clay-colored stools
Action: Contact your clinician promptly for these symptoms. They can assess whether gallbladder tests and follow-up are needed.
Acute kidney injury
Reported, including after fluid loss from vomiting or diarrheaRed-flag symptoms: Persistent nausea, vomiting, or diarrhea that can lead to dehydration
Action: Contact your clinician promptly for ongoing vomiting or diarrhea, trouble keeping fluids down, or signs of dehydration. Do not wait for a fixed number of hours.
Severe hypoglycemia
Risk is increased with insulin or sulfonylureasRed-flag symptoms: Shakiness, sweating, confusion or drowsiness, blurred vision, or a fast heartbeat
Action: Follow the low-blood-sugar plan agreed with your clinician. Contact them about symptoms and ask whether insulin or sulfonylurea doses need review.
Severe allergic reaction (anaphylaxis)
Reported; can be life-threateningRed-flag symptoms: Difficulty breathing or swallowing, swelling of the face, lips, tongue or throat, severe rash or itching, or faintness
Action: Stop Ozempic and get medical help right away for a suspected serious allergic reaction.
The boxed warning: thyroid C-cell tumors
Ozempic carries a boxed warning for thyroid C-cell tumors. This is based on rodent studies; the human risk is unknown.
Ozempic is contraindicated in patients with:
- • Personal or family history of medullary thyroid carcinoma (MTC)
- • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- • A known serious allergic reaction to semaglutide or any Ozempic ingredient
Tell your prescriber about your personal and family thyroid history and any serious medication allergies before starting Ozempic.
Choosing a provider for Ozempic, clinical-oversight specifics
Ask about diabetes care and clinical support before enrolling. Ask whether your clinician will:
- 1. Review your diabetes history, including any retinopathy
- 2. Review insulin, sulfonylureas and other medicines with you
- 3. Explain your individual glucose-monitoring and follow-up plan
- 4. Give you a plan for low blood sugar and urgent symptoms
Confirm whether a service manages type 2 diabetes, how it coordinates with your existing clinician, and who handles questions between visits.
Compare each program's current clinical-oversight evidence in our full rankings.
Overall scores incorporate price, medication options, experience, and transparency as well as oversight; they are not a medical-safety endorsement.
Ask your existing diabetes clinician about continuity of care before changing services.
Our Sprout Health review is a starting point for program research, not a recommendation for managing your symptoms.
Explore program costs and recorded support options in the program finder, or take the 60-second match quiz to explore program options.
Related
- Wegovy side effects deep dive , semaglutide at the higher 2.4mg weight-loss dose
- Zepbound side effects deep dive , tirzepatide for weight loss
- Mounjaro side effects deep dive , tirzepatide, another medicine approved for type 2 diabetes
- Foundayo side effects deep dive
- Rybelsus side effects deep dive , oral semaglutide for diabetes (same molecule, fasting protocol)
- Ozempic vs Wegovy: same molecule, different indications , when each is appropriate
- Cross-drug GLP-1 side effects comparison
- Ozempic lawsuit tracker
- FDA warning letter tracker
- Provider safety checker , questions and checks to use before enrolling
Sources
- Ozempic (semaglutide) FDA-approved prescribing information, Novo Nordisk
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6), NEJM 2016
- FDA MedWatch, adverse event reporting
- 988 Suicide & Crisis Lifeline
This page is for informational purposes only and is not medical advice. Always discuss medication decisions with a licensed prescriber.
Ozempic injection is FDA-approved to improve blood-sugar control in adults with type 2 diabetes. Its indication to reduce the risk of major cardiovascular events is for adults with T2DM and established cardiovascular disease.
Side-effect rates are population averages from clinical trials and may not reflect your individual experience. If you are experiencing a medical emergency, call 911.